Liver Cancer News 2021

Blue Faery: The Adrienne Wilson Liver Cancer Association

AA

A A

Liver Cancer News 2021

Print Friendly, PDF & Email

Click on the title to read the rest of the Liver Cancer News story.

September 2021

How to Choose Second-Line Treatment For Hepatocellular Carcinoma

PSMA PET Imaging More Accurate Than CT In Detecting Hepatocellular Carcinoma

Pembrolizumab Extends OS In Pretreated Hepatocellular Carcinoma

Deep Learning Model Could Predict OutcomesFor HCC Patients

Dr. Harris On Remaining Questions With Treatment Sequencing In HCC

Merck Grabs Lifeline For Problematic Keytruda Liver Cancer Approval Thanks To Asian Trial Win

Cancer Care Innovations: Recently Approved Therapy Improves The Odds For Liver Cancer Patients

Owkin And Cleveland Clinic Develop AI Model That Predicts Liver Cancer Prognosis

Estimating Surgical Outcomes For Hepatocellular Carcinoma

Blood Test For Liver Cancer Shows Promise

Researchers Discover Genetic And Epigenetic ‘Origin Story’ Of Pediatric Liver Cancer

Unique Sugar Structures Could Identify Early-Stage Liver Cancer

Predicting Which Patients Will Develop HCC After HCV Treatment

New Nano Particles Suppress Resistance To Cancer Immunotherapy

The LEGACY Study In HCC

First UK Patients Treated For Liver Cancer Using Ultrasound Technology

Maintaining Virologic Response Following HBV Treatment Reduces HCC Risk

Study RevealsRrates Of The Most Common Form Of Liver Cancer Are Rising In Rural Areas While Slowing In Urban Areas

Wake Forest School Of Medicine Research Shows Radio-Wave Therapy Is Safe for Liver Cancer Patients And Improves Overall Survival

Thiazolidinedione Use Associated With Decreased HCC Risk In Asian Patients With T2D

Galecto Announces First Patient Treated In Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 In Liver Cirrhosis

Harbour BioMed Announces Phase I Study Positive Results On Next-Generation Anti-CTLA-4 Antibody HBM4003

Poorly Differentiated Tumor Size Linked To Worse Prognosis In HCC, Study Finds

Mirror Biologics, Inc. Announces Initial Clearance For Phase II/III Clinical Trial (ALIVE) In Advanced Liver Cancer

Frontline IO For Advanced HCC

FDA Grants Breakthrough Device Designation To The NovoTTF-200T™ System For Advanced Liver Cancer

Dr. Llovet On Considering Safety Profiles During Treatment Selection In HCC

High Interferon Signaling And Antigen Presentation Is Predictive of Response To Upfront Treatment Of Advanced HCC

Adaptimmune Updates Data From Its Phase 1 Trial For Liver Cancer At ILCA Showing Clinical Benefit

Checkpoint Inhibition Plus Ablation Shows Promise In Advanced HCC

Dr. Pinato On Guidelines For Toxicity Management In HCC

Investigators Look To Overcome Resistance In Advanced HCC With Triplet Combinations

Understanding The Molecular Diverse Makeup Of Hepatocellular Carcinoma

Multidisciplinary Approach Important For Successful HCC Care

Predictive Biomarkers For Checkpoint Inhibition Remain Unmet Need In HCC

Dr. Harris On IMbrave150 Results With Atezolizumab/Bevacizumab In HCC

Neoadjuvant Cabozantinib/Nivolumab Leads To Improved Resection Rates In HCC

Radio Waves Show Promise In Treating Hepatocellular Carcinoma

Tislelizumab’s Activity In Pretreated HCC Leads To Randomized Phase 3 Trial

August 2021

Results Of The Study Of Tislelizumab In Unresectable HCC

Medivir Receives Regulatory Approval From MHRA For Phase 1/2a Combination Study With MIV-818

A Turncoat Protein Allows Viruses To Ride Roughshod In The Liver, Paving The Way To Cancer

Identification Of Novel Potential Biomarker For Hepatocellular Carcinoma

Breakthrough Cancer Treatment Now Being Offered At Enloe Medical Center

Combination Treatment May Make Liver Cancer Patients Eligible For Curative Surgery

Determining The Efficacy Of Neoadjuvant Cemiplimab In Hepatocellular Carcinoma

Precision1 Trial May Allow For Precision Medicine In Liver Cancer By Integrating MRI With Whole Genome Sequencing

Hub Candidate Network For Hepatocellular Carcinoma

Advice On Molecular Testing And Sequencing In Unresectable HCC

Study Highlights Exact Sciences’ Blood Test For Liver Cancer 

Utilizing Tislelizumab To Treat Unresectable Hepatocellular Carcinoma

Sintilimab Plus IBI305 For Hepatitis B Virus-Positive Hepatocellular Carcinoma

Dr. Harris On The Adoption Of Immunotherapy In Advanced HCC

Dr. Wang On The Rationale For Viral Hepatitis Screening To Prevent HCC

Yale’s Digestive Diseases Faculty Acknowledged For Expertise

Magnetic Nanoparticles Could Enhance The Efficacy Of Cancer Immunotherapy

Diagnostic Testing For Early-Stage HCC

Screening For Early-Stage HCC

Global Real-World Data Establish TheraSphere Y-90 As Optimal Choice For HCC

Older Liver Cancer Survivors Are Less Informed About Life After Cancer

Digital Health Platform 111 Signs Deal To Build Online Liver Cancer Management Platform

Biotech Company Looking To Detect HCC Early With Liquid Biopsy Based On Microbiome

Direct Acting Antivirals Safe, Effective For HCC Patients

Neoadjuvant Cabozantinib/Nivolumab May Make Resection Possible For Some Patients With Liver Cancer

Curing Hepatitis C Improves Liver Cancer Outcomes

Singapore Study To Aid Early Detection Of Primary Liver Cancer

Study Shows Safety And Efficacy Of Radio-Wave Therapy For Liver Cancer Patients

July 2021

Radio-Wave Therapy is Safe for Liver Cancer Patients and Shows Improvement in Overall Survival, Study Suggests

Drug Combination Could Make Curative Surgery Possible for Some Liver Cancer Patients

World Hepatitis Day 2021 – All You Need to Know About Hepatitis and Liver Cancer

Bristol Myers Squibb Withdraws Single-Agent Nivolumab Post-Sorafenib HCC Indication in the United States

What to Know About Tecentriq (Atezolizumab)

Chinese Study Finds That Sintilimab and Biosimilar Bevacizumab Prolong HCC PFS

Donafenib Bests Sorafenib in Chinese Patients With Advanced Hepatocellular Carcinoma

Treatment for Liver Cancer: From Sorafenib to Natural Products.

2 Novel Studies Set to Address Unanswered Questions in Liver Cancer

Researchers Discover a Culprit Behind Aggressive Liver Cancer

Study Sheds Light on Precise Personalized Hepatocellular Carcinoma Medicine

COVID-19 Pandemic Had Significant Impact on Liver Cancer Screenings and Care

Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study

TARE Proves Effective as First-Line Treatment for HCC

Fourth-Generation Chimeric Antigen Receptor T Cells for Hepatocellular Carcinoma

Study Identifies MAGEA3 as Novel Therapeutic Target in Hepatocellular Carcinoma

Novocure Issues Final Phase 2 Liver Cancer Results; Plans Phase 3 Trial

June 2021

Frontline Lenvatinib Shows Superiority to Sorafenib in HCC in Real-World Setting

Patient-Reported Outcomes With Atezolizumab/Bevacizumab Indicative of Benefit in Unresectable HCC

International Study Explores Novel Combination of Pembrolizumab Plus Quavonlimab and Lenvatinib in Advanced HCC

Glucose Variability Predicts HCC in Patients with Diabetes

Cabozantinib Plus Atezolizumab Extends PFS For Frontline HCC In COSMIC-312 Trial

Genetic Tool Possible Key To Improving Liver Cancer Treatments

Sirnaomics Doses First Patient In Phase 1 U.S. Clinical Study Of STP705 For Treatment Of Liver Cancer

Study Suggests Better Prediction Model For Selecting Transplant Patients To Treat Liver Cancer

Genetic Study Of Liver Cancer Reveals New Drug Target

Camrelizumab And Apatinib Shows Long-Term OS Benefit In Advanced HCC

Study Suggests Drinking 3 To 4 Cups Of Coffee A Day Reduces Risk Of Liver Cancer And Disease

Byvasda Shows Promise In Combination With Sintilimab For Patients With HCC

Berry Oncology Partners With Alibaba Health To Create China’s Early Cancer Screening Ecosystem

University Of Louisville Receives $11.3 Million From NIH For Liver Research Center

Hepatic Arterial Infusion Chemotherapy Prolongs OS Vs. Sorafenib In HCC Subset

HBV Suppression Lowers Liver Cancer Rates In Patients Coinfected With HIV

Liver Cancer Patients To Benefit From Microwave Ablation At QAH

Hepatocellular Carcinoma & HIV

Atezolizumab-Bevacizumab Better Than Sorafenib In Advanced HCC

Surface Oncology, Roche Studying IL-27 Antibody With Tecentriq, Avastin In Liver Cancer 

Geneos Therapeutics Announces Clinical Updates On Personalized Cancer Vaccine Program

Therasphere Proves Highly Effective In HCC

Ultrasound Technology Developed At U-M Now In Clinical Trials For Liver Cancer

Investigators Are Exploring Neoadjuvant And Adjuvant Therapy In HCC

Neoadjuvant Cemiplimab Induces Tumor Necrosis In Resectable HCC

May 2021

Oncotech Develops AI-Powered Real-Time Mobile Cancer Screening And Detection System

Once Only Available In Major Cities, Robot-Assisted Liver Cancer Resection Now Performed In RI

Medivir Announces The Design Of Its Upcoming MIV-818 Combination Study

The Role Of Probiotics In Cancer Prevention Receives Increasing Attention

Atezolizumab-Bevacizumab Better Than Sorafenib In Advanced HCC

Resection May Be Best Option In Patient Subset With Hepatocellular Carcinoma And PVTT

Penn Medicine Study Suggests Long-term Suppression Of Hepatitis B In Patients Who Are HIV-coinfected May Lower Cancer Risk

Non-Invasive Screening: Innovative Technology May Halt Progression Of Liver Disease To Liver Cancer

Fluorescent Dye Helps Guide Pediatric Liver Tumor Resection

Neoadjuvant Cemiplimab Shows Promise As HCC Treatment

More Reimbursement Needed For Hepatocellular Carcinoma

Analysis Correlates Cost Of Therapy With Improvement In Outcomes For Patients With HCC

Oregon State Researchers Discover New Class Of Cancer Fighting Compounds

Dr. Patel On Selecting Patients For Treatment With Atezolizumab/Bevacizumab In HCC

Harbour BioMed Announces Dosing Of First Patient In Australia For Phase Ib/IIa Clinical Study Of Its Next-Generation Anti-CTLA-4 Antibody

Neoadjuvant Libtayo Shows Promise For Patients With Hepatocellular Carcinoma

DOORwaY-90 Study For SIR-Spheres® Therapy As First-Line Treatment For Hepatocellular Carcinoma Enrolls First Patient

Apatinib As Second-line Or Later Therapy In Patients With Advanced Hepatocellular Carcinoma (AHELP)

Vuno’s AI Platform Finds Biomarker For Survival Of Liver Cancer Patients

Tiziana Announces Strategic Initiative For Further Clinical Development Of Milciclib In Patients With Advanced Hepatocellular Carcinoma

How Tumor Cells Control Their Environment To SurviveLandmark Study Launched To Detect Liver Cancer Early In Singapore

April 2021

ODAC Opposes Ongoing FDA Approval of Nivolumab For HCC In Patients Pretreated With Sorafenib

Atezolizumab/Bevacizumab Combo Sets the Standard for New Doublets in Advanced HCC

ODAC Unanimously Backs Pembrolizumab for Second-line Advanced HCC

Helio Health and National Cancer Center Awarded Grant to Evaluate Helio Liver Test in Real-World Screening

The Need for Novel Neoadjuvant Therapies in HCC

7 Reasons Why You Should Drink Moringa Tea

UMCG Studies Cannabis Oil For Liver Cancer Patients With No Further Treatment Options

How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma

Artificially Sweetened Soda May Raise Liver Cancer Risk

Dr. Charlton on the Effects of the COVID-19 Pandemic on HCC

Medivir Has Determined the Starting Dose for the Next Part of the Phase Ib Study With MIV-818

New Combo Shows Benefit Even in Patients With High-Risk HCC

Neoadjuvant Cemiplimab Elicits Complete Pathological Responses in HCC

Liver Cancer Cases Leap Among Men in Scotland

A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis

Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCC

Blue Faery Gives Annual Liver Cancer Research Award

Updated Data Confirm Clinical Benefit of Novel Immunotherapy Combos in HCC

LEGACY Trial of Radioembolization Shows Practice-Changing Data in HCC

Study Shows Significantly Better Performance Characteristics of Epigenomics’ Liver Cancer Panel Compared to the Current Standard of Care for the Early Detection of HCC

Gene Discovery Suggests New Treatment Approach for Liver Cancer

Can-Fite BioPharma (CANF) Announces Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

Protein-Based Biomarker Identifies the Chemo Drug Sensitivity

Burst of Treatment Options in HCC Complicates Sequencing Decisions

March 2021

Continued Demand for Hepatocellular Carcinoma Surveillance

Last Patient With Liver Cancer Included in the Monotherapy Part of Medivir’s Phase Ib Study with MIV-818

Regorafenib/Nivolumab Proof Of Concept Suggested In Third-Line, Refractory HCC

Study In ‘Nature’ Concludes Immunotherapy Is Less Efficient In Non-Viral Liver Cancer

Genetron Health Releases New Data Results Of HCCscreen™ For Liver Cancer Early Screening In China

What to Know About Yervoy (Ipilimumab)

No Evidence That The Milk Protein Casein Causes Cancer

TheraSphere SIRT Received FDA Approval For Treatment Of Unresectable HCC

FDA Approves TheraSphere Y-90 Glass Microspheres For Unresectable HCC

As FDA Review Approaches, Finn Reflects On The Utility of Pembrolizumab, Nivolumab In HCC

Dr. Pillai On Sequential Treatment In HCC

Liver Cancer Symptoms: Pain Near the Right Shoulder Blade Could Be A Sign Of The Disease

The Non-Alcoholic Fatty Liver Cause Of Hepatocellular Carcinoma

People With HIV And Hepatitis B Should Have Ongoing Monitoring For Liver Cancer

Microwave Ablation Burns Away Liver Tumors

Looking Beyond Atezolizumab/Bevacizumab For The Treatment Of HCC

St George Hospital Researchers Make Liver Cancer Breakthrough

How Real-World Regorafenib Dosing Correlates With Prior Sorafenib Treatment In HCC

How Summer On The Lake May Impact Your Liver

Doctors Debate: Is Systemic Or Liver-Directed Therapy Best For Hepatocellular Carcinoma?

TGH Begins Trial of New Device Created To Destroy Tumors Without Surgery

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring Of Liver Disease

Study Shows Simple Blood Test Could Detect Liver Injury Earlier

What Is Stage 4 Liver Cancer?

NICE Recommends New Advanced Liver Cancer Treatment

Implanted Chemotherapy Device Has Kept Her Cancer In Check For More Than A Year

Liver Cancer: What Are The Best Treatment Available? Know What Increases Your Risk of The Deadly Disease

Personalized Radioembolization Improves OS Vs Standard Dosing In Advanced HCC

February 2021

Q&A: Longest Survival Among HCC Patients Seen With ‘Breakthrough’ Drug Combination

Why Is Liver Cancer More Lethal For Black Patients?

Zhejiang University: ZJU Scientists Report Advances In Hepatocellular Carcinoma

Berry Oncology Announces Novel Diagnostic Method for Liver Cancer Achieved Greater Accuracy and Sensitivity

ZJU Scientists Report Advances In Hepatocellular Carcinoma

Can-Fite BioPharma (CANF) New Positive Data From Its Liver Cancer Phase II Clinical Study With Namodenoson

Cancer Control: Non-DNA Changes Induce Metabolism Variations In Hepatocellular Carcinomas

Neoadjuvant Cabozantinib/Nivolumab Feasible For Borderline Resectable Patients With HCC

Dr. Mody On Progress Made With Y-90 In Hepatocellular Carcinoma

Abivax’s Phase I/II ABX196 In Second-Line HCC Draws Odds If Front-Line Shake-Up Negatively Impacts Its Success Trajectory

Never-Before-Seen Antibody Binding, Informing Liver Cancer, Antibody Design

New Standard Of Care In Hepatocellular Carcinoma Shifts The Treatment Paradigm To A Grey Area

Incidence Of Liver Cancer Increases Significantly Among People With HIV

Gentle Stroll On Treadmill Helps Prevent Liver Cancer

Challenges When Treating Patients With Hepatocellular Carcinoma

Ionic Liquid Formulation Uniformly Delivers Chemotherapy To Tumors While Destroying Cancerous Tissue

Genetron Health’s Early Liver Cancer Screening Research Results Included In First Prevention And Treatment Guidelines For Patients In China

Drug Combo May Boost Survival For Tough-To-Treat Liver Cancers

Innovent Announces First Patient Dosed In Phase III Pivotal Trial Of IBI310 (CTLA-4) Combined With TYVYT® For The Treatment Of First-Line Advanced Hepatocellular Carcinoma

RDI And Ammonia Levels May Predict Tolerability Of Lenvatinib In HCC

Drug ‘Breakthrough’ Gives Longest-Ever Survival In Nonresectable Liver Cancer Patients

Watch A New “Love Your Liver” Video Each Day In February!

Eisai’s Liver Cancer Drug Lenvima Threatens Bayer’s Nexavar

Liver Cancer ‘Signature’ In Gut Holds Clues To Cancer Risk

Liver Cancer Still 2nd Major Cause Of Cancer Deaths In Korea

Real-World Data For Lenvatinib Is Similar To Clinical Trials

Can-Fite Announces Inhibition Of Liver Fibrosis By Cannabis Compounds In Preclinical Studies

Targeted RNA Nanoparticle Shows Early Promise As Treatment For Liver Cancer

January 2021

Redefining BCLC B, Intermediate-Stage HCC: Is There A Role For Combination Systemic Therapy

Pembrolizumab Not Cost-Effective For Second-Line Treatment Of HCC In The US

FDA Clearance For Hepatica, Perspectum’s Surgical Decision Support Tool For Liver Cancer

Jellyfish Venom Stops Cancer Cell Growth In Lab Trial

FDA Grants Orphan Drug Designation To Uttroside-B For Liver Cancer

Evidence Grows For Avoiding Biopsy In Hepatocellular Carcinoma

Post-Treatment Alpha-Fetoprotein Reduction Prognostic For Survival Outcomes In HCC

Hepatocellular Carcinoma: Support For The Fourth Leading Cancer-Related Cause Of Death

Patients With Advanced HCC Often Do Not Receive Second-Line Therapy In Real-World Practice

Pembrolizumab Monotherapy May Play Role In Treatment-Naive HCC

Hepatocellular Carcinoma Treatment Landscape Evolving By The Minute

Second-Line Pembrolizumab Shows Continued OS And PFS Improvement In Advanced HCC

Japanese Team Develops Cancer Detector Using Mosquito’s Sense Of Smell

Lenvatinib Monotherapy Demonstrates Efficacy In The First Line For HCC

Validated Risk Score Predicts Post-Transplant Survival In HCC

Scoring System To Redefine How U.S. Patients Prioritized For Liver Transplant

Zhongchao Inc. Promotes Standardized Liver Cancer Diagnosis And Treatment

Frontline Treatment Arsenal Expands In Advanced HCC

Liver Stiffness Before Hepatitis C Treatment Predicts Liver Cancer Risk

Real-World Findings In REFINE Study Support Use Of Regorafenib In HCC

Liver Cancer Cells Cause Stromal Cells To Secrete Protein That Enhances Tumor Growth

Immunotherapy With Radiotherapy Could Improve Outcomes Of Cancers In Liver

Comparable Survival Observed With Regorafenib In HCC In Real-World Versus Clinical Settings

Immunicum AB Receives FDA Orphan Drug Designation For Ilixadencel As A Treatment HCC

For past liver cancer news, please visit our Liver Cancer News Archives.